Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsSTU:FLB -6.29%39 Days Payable is 61.89 as of Mar. 2026, which is 34% above its 10-year median of 46.23. GuruFocus rates STU:FLB with a GF Score™ of 39/100 and a GF Value™ of €0.46 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Standard BioTools ranks worse than 52.64% on this metric.
The historical rank and industry rank for Standard BioTools's Days Payable or its related term are showing as below:
STU:FLB'
s Days Payable Range Over the Past 10 Years
Min: 29.3 Med: 46.23 Max: 65.75
Current: 65.75
During the past 13 years, Standard BioTools's highest Days Payable was 65.75. The lowest was 29.30. And the median was 46.23.
STU:FLB's Days Payable is ranked worse than 52.64% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs STU:FLB: 65.75
Standard BioTools's Days Payable
declined
from Mar. 2025 (84.51) to Mar. 2026 (61.89).
It may suggest that Standard BioToolsaccelerated paying its suppliers.
Standard BioTools Days Payable Related Terms
Standard BioTools Days Payable Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FLB vs SENS, TMCI, SGHT: Days Payable Comparison
For the Medical Devices subindustry, Standard BioTools's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Days Payable distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Standard BioTools's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (STU:FLB) has a Days Payable of 61.89 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Standard BioTools and its competitors. This is 34% above median its historical median of 46.23. Over the past decade, Standard BioTools' Days Payable has ranged from 29.30 to 65.75. According to the industry distribution chart, Standard BioTools ranks #419 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 52.6%.
Is Standard BioTools' Days Payable too high?
Standard BioTools' current Days Payable of 61.89 is 34% above median its 10-year median of 46.23. Over the past 10 years, this metric has ranged from a low of 29.30 to a high of 65.75. The Medical Devices & Instruments industry median Days Payable is 67.97. Standard BioTools' value of 61.89 is 8.9% below this industry median. Based on the distribution chart, Standard BioTools ranks #419 out of 796 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Standard BioTools has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Days Payable compare to SENS and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #419 out of 796 companies for Days Payable. This places Standard BioTools in the lower half of its industry. The industry median Days Payable is 67.97. Standard BioTools' value of 61.89 is 8.9% below this benchmark. Historically, Standard BioTools' own Days Payable has ranged from 29.30 to 65.75 over the past decade. While the company's 10-year median is 46.23 vs. the industry median of 67.97, Standard BioTools has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current Days Payable of 61.89 is 8.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current Days Payable is 61.89, which is 34% above median its own 10-year median of 46.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.46, compared to a current price of €0.75 — trading 62% above its estimated fair value. The current Days Payable is 61.89, which is 34% above median its 10-year median of 46.23 and 8.9% below the Medical Devices & Instruments industry median of 67.97. Standard BioTools' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Days Payable is 61.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (STU:FLB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued.
The current stock price of €0.75 is trading 62% above its estimated GF Value™ of €0.46.
GuruFocus considers Standard BioTools to be Significantly Overvalued.
Key valuation signals for STU:FLB:
Days Payable: 61.89 (34% above median its 10-year median of 46.23)
GF Value™: €0.46 vs. price of €0.75 (62% above fair value)
Industry Position: 8.9% below the Medical Devices & Instruments median (#419 of 796)
No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
39GF Score
Get the complete analysis for STU:FLB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FLB has been successfully added to your 
